BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

799 related articles for article (PubMed ID: 33685605)

  • 1. Biologics for the Use in Chronic Spontaneous Urticaria: When and Which.
    Maurer M; Khan DA; Elieh Ali Komi D; Kaplan AP
    J Allergy Clin Immunol Pract; 2021 Mar; 9(3):1067-1078. PubMed ID: 33685605
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biologics for chronic spontaneous urticaria: toward a personalized treatment.
    Asero R; Ferrucci S; Tedeschi A; Cugno M
    Expert Rev Clin Immunol; 2022 Dec; 18(12):1297-1305. PubMed ID: 36264653
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New treatments for chronic urticaria.
    Kolkhir P; Altrichter S; Munoz M; Hawro T; Maurer M
    Ann Allergy Asthma Immunol; 2020 Jan; 124(1):2-12. PubMed ID: 31446134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel Therapeutic Approaches and Targets for Treatment of Chronic Urticaria: New Insights and Promising Targets for a Challenging Disease.
    Martina E; Diotallevi F; Bianchelli T; Paolinelli M; Offidani A
    Curr Pharm Biotechnol; 2021; 22(1):32-45. PubMed ID: 32603278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current and Future Approaches in Management of Chronic Spontaneous Urticaria Using Anti-IgE Antibodies.
    Orzan OA; Popa LG; Mihai MM; Cojocaru A; Giurcăneanu C; Dorobanțu AM
    Medicina (Kaunas); 2022 Jun; 58(6):. PubMed ID: 35744079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Omalizumab for treating chronic spontaneous urticaria: an expert review on efficacy and safety.
    Giménez-Arnau AM
    Expert Opin Biol Ther; 2017 Mar; 17(3):375-385. PubMed ID: 28125304
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging treatments for chronic urticaria.
    Wedi B
    Expert Opin Investig Drugs; 2022 Mar; 31(3):281-290. PubMed ID: 35166638
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria.
    Kaplan AP; Giménez-Arnau AM; Saini SS
    Allergy; 2017 Apr; 72(4):519-533. PubMed ID: 27861988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The efficacy of omalizumab treatment in chronic spontaneous urticaria is associated with basophil phenotypes.
    Johal KJ; Chichester KL; Oliver ET; Devine KC; Bieneman AP; Schroeder JT; MacGlashan DW; Saini SS
    J Allergy Clin Immunol; 2021 Jun; 147(6):2271-2280.e8. PubMed ID: 33713769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New biologics in the treatment of urticaria.
    Kocatürk E; Zuberbier T
    Curr Opin Allergy Clin Immunol; 2018 Oct; 18(5):425-431. PubMed ID: 30015639
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How to Treat Patients with Chronic Spontaneous Urticaria with Omalizumab: Questions and Answers.
    Türk M; Carneiro-Leão L; Kolkhir P; Bonnekoh H; Buttgereit T; Maurer M
    J Allergy Clin Immunol Pract; 2020 Jan; 8(1):113-124. PubMed ID: 31374358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic spontaneous urticaria: Focus on pathophysiology to unlock treatment advances.
    Kaplan A; Lebwohl M; Giménez-Arnau AM; Hide M; Armstrong AW; Maurer M
    Allergy; 2023 Feb; 78(2):389-401. PubMed ID: 36448493
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved FcεRI-Mediated CD203c Basophil Responsiveness Reflects Rapid Responses to Omalizumab in Chronic Spontaneous Urticaria.
    Oda Y; Fukunaga A; Washio K; Imamura S; Mizuno M; Hatakeyama M; Ogura K; Nishigori C
    J Allergy Clin Immunol Pract; 2021 Mar; 9(3):1166-1176.e8. PubMed ID: 32898709
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unveiling chronic spontaneous urticaria pathophysiology through systems biology.
    Segú-Vergés C; Gómez J; Terradas-Montana P; Artigas L; Smeets S; Ferrer M; Savic S
    J Allergy Clin Immunol; 2023 Apr; 151(4):1005-1014. PubMed ID: 36587849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atopy and Response to Omalizumab Treatment in Chronic Spontaneous Urticaria.
    Costa C; Esteves Caldeira L; Paulino M; Santos DF; Silva SL
    Int Arch Allergy Immunol; 2024; 185(3):260-266. PubMed ID: 38113870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-TPO IgG/Total IgE Ratio: Biomarker for Omalizumab Response Prediction in Chronic Spontaneous Urticaria.
    Brás R; Esteves Caldeira L; Bernardino A; Costa C
    Int Arch Allergy Immunol; 2023; 184(9):866-869. PubMed ID: 37557083
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Omalizumab may not inhibit mast cell and basophil activation in vitro.
    Gericke J; Ohanyan T; Church MK; Maurer M; Metz M
    J Eur Acad Dermatol Venereol; 2015 Sep; 29(9):1832-6. PubMed ID: 25257818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biologics in Chronic Urticaria.
    Bulkhi A; Cooke AJ; Casale TB
    Immunol Allergy Clin North Am; 2017 Feb; 37(1):95-112. PubMed ID: 27886913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An open-label, proof-of-concept study of lirentelimab for antihistamine-resistant chronic spontaneous and inducible urticaria.
    Altrichter S; Staubach P; Pasha M; Singh B; Chang AT; Bernstein JA; Rasmussen HS; Siebenhaar F; Maurer M
    J Allergy Clin Immunol; 2022 May; 149(5):1683-1690.e7. PubMed ID: 34954198
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biomarkers of Autoimmune Chronic Spontaneous Urticaria.
    Larenas-Linnemann D
    Curr Allergy Asthma Rep; 2023 Dec; 23(12):655-664. PubMed ID: 38064133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.